CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 169 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2022. The put-call ratio across all filers is 0.65 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $95,307,292 | -18.9% | 3,463,201 | 0.0% | 2.01% | -10.1% |
| Q2 2023 | $117,506,410 | +5.9% | 3,463,201 | +12.3% | 2.24% | -3.2% |
| Q1 2023 | $110,970,056 | -19.3% | 3,084,215 | 0.0% | 2.31% | -17.6% |
| Q4 2022 | $137,463,463 | +58.6% | 3,084,215 | 0.0% | 2.81% | +40.4% |
| Q3 2022 | $86,697,000 | +4.3% | 3,084,215 | 0.0% | 2.00% | -6.9% |
| Q2 2022 | $83,150,000 | -20.8% | 3,084,215 | 0.0% | 2.15% | -1.2% |
| Q1 2022 | $105,048,000 | -30.7% | 3,084,215 | -21.4% | 2.17% | -1.8% |
| Q4 2021 | $151,530,000 | -28.2% | 3,921,579 | +0.3% | 2.21% | -30.5% |
| Q3 2021 | $211,044,000 | +61.5% | 3,908,947 | 0.0% | 3.18% | +61.4% |
| Q2 2021 | $130,715,000 | +62.3% | 3,908,947 | 0.0% | 1.97% | +56.9% |
| Q1 2021 | $80,524,000 | +34.3% | 3,908,947 | +14.2% | 1.26% | +25.0% |
| Q4 2020 | $59,968,000 | +29.6% | 3,422,855 | +9.7% | 1.01% | -9.7% |
| Q3 2020 | $46,272,000 | +36.4% | 3,120,137 | +19.5% | 1.11% | +16.6% |
| Q2 2020 | $33,930,000 | – | 2,610,000 | – | 0.96% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 2,600,000 | $88,218,000 | 12.13% |
| Octagon Capital Advisors LP | 759,898 | $25,783,339 | 3.59% |
| TSP Capital Management Group, LLC | 251,895 | $8,546,800 | 3.08% |
| ACUTA CAPITAL PARTNERS, LLC | 122,343 | $4,151,098 | 2.81% |
| 5AM Venture Management, LLC | 310,270 | $10,527,461 | 2.62% |
| COMMODORE CAPITAL LP | 631,665 | $21,432,393 | 2.41% |
| RTW INVESTMENTS, LP | 3,463,201 | $117,506,410 | 2.24% |
| Eversept Partners, LP | 785,740 | $26,660,158 | 2.23% |
| Redmile Group, LLC | 1,696,004 | $57,545,416 | 2.21% |
| Affinity Asset Advisors, LLC | 87,031 | $2,952,962 | 1.03% |